Loading...
•
Dec 31, 2020
ClearPoint Neuro Q4 2020 Earnings Report
Reported record revenues despite COVID-19 related challenges.
Key Takeaways
ClearPoint Neuro reported a revenue of $3.7 million for the fourth quarter of 2020, compared to $3.2 million for the same period in 2019. The company is optimistic about returning to pre-COVID procedure volume in the second half of 2021.
Total revenues were approximately $3.7 million, up from $3.2 million year-over-year.
Functional neurosurgery navigation and therapy product and service revenues decreased 5% year-over-year.
Biologics and drug delivery revenue increased 40% year-over-year.
Capital equipment product and related service revenue increased 41% year-over-year.
Revenue by Segment
Forward Guidance
ClearPoint Neuro is cautiously optimistic about the future, expecting a return to pre-COVID procedure volume in the second half of 2021.
Positive Outlook
- Hospitals are starting to schedule patients for March and April.
- Expectation to return to pre-COVID procedure volume in the second half of 2021.
- Strong balance sheet.
- Stronger position than they started.
- Talented team.
Challenges Ahead
- Closures and postponements related to ICU bed capacity due to the COVID-19 pandemic.
- Not yet in a position to give a forecast for 2021.
- Continuing effects of the COVID-19 pandemic.
- Elective surgical procedures have not yet reached pre-pandemic activity.
- COVID-related closures and postponements.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...